SCHEMBL1616299

SCHEMBL1616299

O=Cc1ccc(-c2ccccc2Cl)o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
POLB P06746 4/20 0.58
LMNA P02545 3/20 0.58
ALDH1A1 P00352 6/20 0.55
MAPT P10636 5/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
MAPK1 P28482 3/20 0.54
HSD17B10 Q99714 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
HPGD P15428 3/20 0.54
GSK3A P49840 2/20 0.54
GSK3B P49841 2/20 0.54
GAA P10253 2/20 0.54
PIK3CG P48736 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
NPSR1 Q6W5P4 2/20 0.53
INSR P06213 1/20 0.52
IGF1R P08069 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16029367 0.86 SIRT2 (0.57) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL30861665 0.86 SIRT2 (0.57) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL2561760 0.83 MAPT (0.52) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL2561763 0.83 MAPT (0.52) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL6420665 0.79 KDM4E (0.46) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL1728691 0.79 MAPT (0.64) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL4697667 0.79 HPGD (0.65) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL31358792 0.78 JAK2 (0.60) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL2321506 0.78 KDM4E (0.58) KDM4EPOLBLMNAALDH1A1MAPT
SCHEMBL3038244 0.78 KDM4E (0.63) KDM4EPOLBLMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105777758-A Sliver ion fluorescence sensor molecule as well as synthesis and application thereof 西北师范大学 2016-07-20 CN claimed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US claimed
EP-1381359-A1 AURONES AS TELOMERASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-21 EP claimed
WO-2002083123-A1 AURONES AS TELOMERASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2002-10-24 WO claimed
WO-2024103400-A1 POLYCYCLIC COMPOUND AS GPR75 ACTIVATOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 水木未来(北京)科技有限公司 2024-05-23 WO disclosed
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 US disclosed
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 US disclosed
EP-3901159-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME Millennium Pharmaceuticals, Inc. (US) 2021-10-27 EP disclosed
EP-3517112-B1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARM INC (US) 2021-04-07 EP disclosed
EP-3226858-B1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS PROCOMCURE BIOTECH GMBH (AT) 2021-02-03 EP disclosed
US-10780090-B2 Heteroaryl compounds useful as inhibitors of SUMO activating enzyme MILLENNIUM PHARMACEUTICALS, INC. (US) 2020-09-22 US disclosed
US-10456379-B2 Imidazole-based antimicrobial agents PROCOMCURE BIOTECH GMBH (AT) 2019-10-29 US disclosed
EP-1128832-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES Viropharma Incorporated (US) 2001-09-05 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed
WO-2001047925-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2001-07-05 WO disclosed
WO-2000032598-A9 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS INC (US) 2000-11-30 WO disclosed
US-6133305-A PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER SUGEN, INC. (US) 2000-10-17 US disclosed
WO-2000032598-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS INC. (US) 2000-06-08 WO disclosed
WO-2000010573-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES VIROPHARMA INCORPORATED (US) 2000-03-02 WO disclosed
US-4035394-A 5-Phenyl-2-furanyl-oxo or-hydroxy alkanoic acids and ethyl esters as gastric acid antisecretory agents MORTON-NORWICH PRODUCTS, INC. (US) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10456379-B2 Imidazole-based antimicrobial agents TLR5, NISCH, SLC11A2 KDM4E 2893/4885POLB 1637/4885LMNA 4548/4885
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 KDM4E 1160/4885POLB 2522/4885LMNA 2130/4885
US-20040132807-A1 Aurones as telomerase inhibitors TERT, TERF2, TERF2IP KDM4E 818/4885POLB 175/4885LMNA 393/4885
US-10780090-B2 Heteroaryl compounds useful as inhibitors of SUMO activating enzyme SAE1, SUMO1, SUMO3 KDM4E 1160/4885POLB 2522/4885LMNA 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.